I've noticed that recently some of the analysts have been realizing that Teva's t-enox delay has to do with something other than that they filed a reply one month after Momenta.
Teva may never say anything unless they were to get a direct no from the fda, and if the fda hasn't said no to Amphastar yet I can't see it declining Teva.